Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23261356 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Conditions: Borderline Ovarian Surface Epithelial-stromal Tumor;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor
Interventions: Drug: selumetinib;   Other: pharmacological study;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years